{'fraction_non_alphanumeric': 0.01644736842105263, 'fraction_numerical': 0.0, 'mean_word_length': 5.920454545454546, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Decreasing the Adverse Effects of Cancer Therapy: An NCI Workshop on the Preclinical Development of Radiation Injury Mitigators/Protectors

The study of radiation mitigators/protectors for use in cancer treatment and management is complex as they must reduce normal tissue toxicity without reducing tumor cell kill. The known toxicology, pharmacokinetic, and mechanistic data for the proposed agent will direct investigators to the appropriate stage of preclinical development. Overall, we hope that this Workshop commentary facilitates the transition of radiation mitigators/protectors into clinical trials.